Provectus Biopharmaceuticals, Inc. (ticker PVCT) filed a Form 8-K with the Securities and Exchange Commission on June 18, 2026, furnishing the slide presentation for its 2026 annual meeting of stockholders under Item 7.01, Regulation FD Disclosure. The filing lists the same June 18, 2026 date as the date of the earliest event reported and attaches the deck as Exhibit 99.1. Under Item 9.01, the company also lists Exhibit 104, the cover-page inline XBRL data file.

The 8-K describes the purpose of the disclosure in a single sentence. Per the filing, the presentation accompanies the company’s annual stockholder meeting and is meant to give shareholders a status update across the company’s operating functions. The filing identifies Provectus as a Delaware-incorporated registrant headquartered at 800 S. Gay Street, Suite 1610, Knoxville, Tennessee, under Commission File Number 001-36457.

"During its annual meeting of stockholders to be held on June 18, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) will provide an update about the Company’s clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities."— Provectus Biopharmaceuticals Form 8-K, Item 7.01, source

Furnished, not filed: what Item 7.01 means here

The 8-K is explicit that this disclosure is being furnished rather than filed. The filing states that, pursuant to SEC rules and regulations, the information in the Item 7.01 disclosure, including Exhibit 99.1 and the information set forth in it, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended. That distinction is standard for Regulation FD disclosures: furnishing places the material on the public record so all investors have simultaneous access, while keeping it outside the liability framework that attaches to formally filed reports and limiting its automatic incorporation by reference into other filings.

Regulation FD, the rule that Item 7.01 implements, requires that when an issuer discloses material nonpublic information it does so broadly rather than selectively. Releasing the annual-meeting deck through an 8-K is one mechanism companies use to satisfy that requirement around a scheduled investor event, ensuring the same materials shown to attending stockholders are available to the wider market at the same time.

What the filing discloses about the deck

The 8-K itself does not reproduce the substance of the slides in text; the deck is attached as Exhibit 99.1 and incorporated by reference. As furnished to EDGAR, Exhibit 99.1 is a set of presentation pages, and the cover document points to the exhibit as the source for the underlying content. Beyond naming the topic areas the presentation addresses — clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development — the body of the 8-K does not quantify results, name specific programs, or state outcomes. Readers seeking the operational detail are directed by the filing to the exhibit itself.

The cover page records additional registrant facts. Provectus checked that it is not an emerging growth company, and for the section listing securities registered under Section 12(b) of the Exchange Act the filing states “None.” The SEC’s EDGAR company record classifies Provectus under Standard Industrial Classification code 2834, Pharmaceutical Preparations, and shows the registrant’s prior corporate names, including Provectus Pharmaceuticals, Inc. and, earlier, SPM Group Inc. and Zamage Digital Imaging Inc., before the current name.

Who signed and what comes next on the record

The report was signed on behalf of the registrant by Heather Raines, identified in the filing as Chief Financial Officer and Principal Financial Officer, and is dated June 18, 2026. The two exhibits listed in the filing are Exhibit 99.1, described as the “2026 Annual Meeting of Stockholders presentation slides,” and Exhibit 104, the cover-page interactive data file whose XBRL tags are embedded in the inline XBRL document. The accession number for the submission is 0001493152-26-029280.

For investors tracking Provectus, the document on the public record at this stage is the furnished presentation and the cover 8-K that transmits it. The filing does not, by its own text, announce a financing, a licensing agreement, a clinical readout, or a regulatory decision; it sets out the format and scope of an annual-meeting update and makes the accompanying slides publicly available. Any material specifics about the company’s clinical, regulatory, manufacturing, intellectual-property, or business-development activities reside in Exhibit 99.1 as furnished to the SEC, and that exhibit is the primary document for the operational claims the deck contains.